To this end, repeated on‐treatment levels of soluble DCN were analysed in 124 patients enrolled in the CHAMP study, followed by mapping of DCN and the associated immune landscape in resected tumours using multiplexed immunofluorescence. Here, DCN is linked to neoplasm.